TriSalus Life Sciences (TLSIW) Preferred Stock Liabilities (2020 - 2023)

TriSalus Life Sciences (TLSIW) has 4 years of Preferred Stock Liabilities data on file, last reported at $12.0 million in Q2 2023.

• For the quarter ending Q2 2023, Preferred Stock Liabilities fell 95.18% year-over-year to $12.0 million; the trailing twelve-month figure through Jun 2023 stood at $12.0 million (down 95.18% YoY), and the FY2022 full-year result was $164.0 million, up 2.18% from the prior year.
• Preferred Stock Liabilities for Q2 2023 stood at $12.0 million, down from $20.2 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $250.0 million in Q2 2022 and bottomed at $12.0 million in Q2 2023.
• The 4-year median for Preferred Stock Liabilities is $250.0 million (2020), against an average of $183.7 million.
• The widest annual swing landed in 2022, when Preferred Stock Liabilities grew 2.18%; it then plunged 95.18% in 2023.
• A 4-year view of Preferred Stock Liabilities shows it stood at $250.0 million in 2020, then plunged by 35.8% to $160.5 million in 2021, then rose by 2.18% to $164.0 million in 2022, then tumbled by 92.66% to $12.0 million in 2023.
• The last three Preferred Stock Liabilities figures came in at $12.0 million (Q2 2023), $20.2 million (Q1 2023), and $164.0 million (Q4 2022), per Business Quant data.

Peer Comparison